Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line

Biochemical Pharmacology

Volumn 55, Issue 5, 1998, Pages 667-676

  Guichard, Sylvie ^a,b   Hennebelle, Isabelle ^a   Bugat, Roland ^a,b   Canal, Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

5 Fluorouracil; CPT 11; DNA protein complexes; Synergism; Thymidylate synthase; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CULTURE; CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; ENZYME INHIBITORS; FLUOROURACIL; HT29 CELLS; HUMANS; S PHASE; THYMIDYLATE SYNTHASE;

EID: 0032032201     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00541-8     Document Type: Article

References (48)

1. 1. Wang JC, DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
2. 2. Wall ME, Wani MC, Cook CE, Plumer KH, McPhail AT and Sim GA, Plant antitumor agents. I. The isolation and structure of camptothecin, a novel, alkaloidal leukemia and tumor inhibitor from Canptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
3. 3. Gottlieb JA, Guarino AM and Call JB, Preliminary pharmacological and clinical evaluation of camtothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470, 1970.
4. 4. Moertel CG, Schutt AJ and Reitemeier RJ, Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
5. 5. Muggia FM, Creaven PJ and Hansen H, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880); Correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
6. 6. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M and Rougier P, CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-1287, 1995.
7. 7. Burris HA, Rothenberg ML, Kuhn JG and Von Hoff DD, Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19: 663-669, 1992.
8. 8. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M, DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
9. 9. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK et al., Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107, 1991.
10. 10. Rothenberg M, Eckardt JR, Kuhn JG, Burris HAR, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ and Von-Hoff DD, Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135, 1996.
11. 11. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Natner M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P and Mahjoubi M, Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997.
12. 12. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K, Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect: of CPT-11. Cancer Res 51: 4187-4191, 1991.
13. 13. Hertzberg RP, Caranfa MJ and Hecht S, On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638, 1989.
14. 14. Avemann K, Knippers R and Koller T, Camptothecin, a specific inhibitor of type I DNA topoisomerase I, induces DNA breakage at replication forks. Mol Cell Biol 8: 3026-3034, 1988.
15. 15. Hsiang YE, Lihou MG and Liu LF, Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
16. 16. Zhang H, D'Arpa P and Liu LF, A model for tumour cell killing by topoisomerase poisons. Cancer Cells 2: 23-27, 1990.
17. 17. Diasio RB and Harris BE, Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237, 1989.
18. 18. Sobrero AF, Aschele C and Bertino JR, Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15: 368-381, 1997.
19. 19. Guichard S, Cussac D, Hennebelle I, Bugat R and Canal P, Sequence-dependent activity of the irinotecan - 5FU combination in human colon cancer model HT-29 in vitro and in vivo. Int J Cancer, in press.
20. 20. Aschele C, Baldo C, Guglielmi A, Sobrero A and Bertino JR, Sequence-dependent synergism between tomudex and irinotecan in human colon cancer cells in vitro. 9th NCI EORTC Symposium on new drugs in cancer therapy, Abstract 302, 88, 1996.
21. 21. Erlichman C, Svingen PA, Mullany SA and Kaufmann SH, Synergistic interaction of SN-38 and 5FU/leucovorin. Proc Am Assoc Cancer Res 37: 294, 1996.
22. 22. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S and Miura Y, Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604-610, 1992.
23. 23. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehowet RC and Rowinsky EK, Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734-741, 1996.
24. 24. Mans DRA, Brondani da Rocha A, Vargas Schwartzbold C and Schwartsmann G, Assessment of the efficacy of the irinotecan - 5 fluorouracil combination in a panel of human coton carcinoma cell lines. Proc Am Assoc Cancer Res 37: 291, 1996.
25. 25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
26. 26. Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y and Saijo N, Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14: 104-107, 1985.
27. 27. Barilero I, Gandia D, Armand JP, Mathieu Boue A, Re M, Gouyette A and Chabot GG, Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J Chromatogr 575: 275-280, 1992.
28. 28. Rivory LP and Robert J, Reversed-phase high-performance liquid Chromatographic method for the simultaneous quantitation of the carboxylate and tactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 661: 133-141, 1994.
29. 29. Bradford MM, A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
30. 30. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Renée N and Milano G, A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522, 1994.
31. 31. Wang Z and Sinha BK, Interleukin-1a-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Mol Pharmacol 49: 269-275, 1996.
32. 32. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S and Gonzalez C, Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996.
33. 33. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P and Kelsen DP, Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14: 2959-2967, 1996.
34. 34. Saltz L, Shimada Y and Khayat D, CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 32A(suppl.3): S24-S31, 1996.
35. 35. Pizzorno G, Sun Z and Handschumacher RE, Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 49: 553-557, 1995.
36. 36. Peters GJ, Pinedo HM, Ferwerda W, de Graaf TW and van Dijk W, Do antimetabolites interfere with the glycosylation of cellular glycoconjugates? Eur J Cancer 26: 516-523, 1990.
37. 37. Kessel D, Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil. Cancer Res 40: 322-324, 1980.
38. 38. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y, Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842, 1994.
39. 39. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F and Pommier Y, Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34: 7200-7206, 1995.
40. 40. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC and Elgin SCR, Drosophila DNA topo-isomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81: 6958-6962, 1984.
41. 41. Bohr VA, Phillips DH and Hanawalt PC, Heterogeneous DNA damage and repair in the mammalian genome. Cancer Res 47: 6426-6436, 1987.
42. 42. Downes CS and Johnson RT, DNA topoisomerases and DNA repair. BioEssays 8: 179-184, 1988.
43. 43. Stevnsner T and Bohr VA, Studies on the role of topoisomerases in general, gene-and strand-specific DNA repair. Carcinogenesis 14: 1841-1850, 1993.
44. 44. Boothman DA, Wang M, Schea RA, Burrows HL, Strickfaden S and Owens JK, Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 24: 939-948, 1992.
45. 45. Pourquier P, Ueng LM, Kohlhagen G, Mazumber A, Gupta M, Kohn KW and Pommier Y, Effects of Uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 272: 7792-7796, 1997.
46. 46. van Laar JAM, ven der Wilt CL, Rustum YM, Noordhuis P, Smid K, Pinedo HM and Peters GJ, Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin Cancer Res 2: 1327-1333, 1996.
47. 47. Chen AY, Okunieff P, Pommier Y and Mitchell JB, Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57: 1529-1536, 1997.
48. 48. Tsao YP, D'Arpa P and Liu LF, The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 52: 1823-1829, 1992.